Redwire (NYSE:RDW) management used its full-year and fourth-quarter 2025 earnings call to highlight what CEO Peter Cannito described as a significant shift in the business, driven in part by the June ...

Arcus Biosciences (NYSE:RCUS) used its fourth-quarter and full-year 2025 earnings call to highlight updated clinical data for its lead oncology program, casdatifan, and to outline near-term plans for ...